We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are you a frequent visitor to retail drugstores? Then you must have come across at least one of the 13,100 drugstores operated by Walgreens Boots Alliance, Inc. (WBA - Free Report) . This Illinois-based company is the first global pharmacy-led, health and wellbeing enterprise.
Currently, Walgreens Boots has a Zacks Rank #3 (Hold) but that could change following its impressive third quarter fiscal 2017 earnings report which has just released.(You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key details from the just-released announcement below:
Earnings: Walgreens Boots’ adjusted earnings per share of $1.33, up 12.7% year over year surpassed the Zacks Consensus Estimate figure of $1.31.
Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise
Revenues: Walgreens posted revenues of $30.11 billion grew 2.1% year over year which is ahead of the Zacks Consensus Estimate of $29.68 billion
Key Stats: In the reported third quarter fiscal 2017, revenues from the Retail Pharmacy USA division increased 6.3% to $22.5 billion, while revenues from the Pharmaceutical Wholesale division fell 7.9% to $5.3 billion. Revenues from the Retail Pharmacy International division also dropped 10.3% to $2.8 billion. Moreover, Walgreens Boots filled 255.2 million prescriptions (including immunizations) on a 30-day adjusted basis in the quarter, reflecting an increase of 8.5% over third quarter of fiscal 2016.
Major Factors: Per management, Walgreens Boots third quarter 2017 results were in line with its expectations. This is on account of the company’s strategic tie-ups which brought more patients to its U.S. pharmacies. This also led to its highest reported quarterly retail prescription market share in the U.S. Management is currently optimistic about its ongoing cost transformation program and remains confident about the long term growth of the company. The company has increased the lower end of its outlook for fiscal year 2017 by 8 cents per share and anticipates adjusted earnings per share of $4.98 to $5.08.
Stock Price: Following the earnings release, share prices rose 3.77% during the pre-market trading session.
Check back later for our full write up on this Walgreens Boots earnings report later!
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Walgreens Boots (WBA) Tops Q3 Earnings, Revenues Estimates
Are you a frequent visitor to retail drugstores? Then you must have come across at least one of the 13,100 drugstores operated by Walgreens Boots Alliance, Inc. (WBA - Free Report) . This Illinois-based company is the first global pharmacy-led, health and wellbeing enterprise.
Currently, Walgreens Boots has a Zacks Rank #3 (Hold) but that could change following its impressive third quarter fiscal 2017 earnings report which has just released.(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key details from the just-released announcement below:
Earnings: Walgreens Boots’ adjusted earnings per share of $1.33, up 12.7% year over year surpassed the Zacks Consensus Estimate figure of $1.31.
Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise
Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise | Walgreens Boots Alliance, Inc. Quote
Revenues: Walgreens posted revenues of $30.11 billion grew 2.1% year over year which is ahead of the Zacks Consensus Estimate of $29.68 billion
Key Stats: In the reported third quarter fiscal 2017, revenues from the Retail Pharmacy USA division increased 6.3% to $22.5 billion, while revenues from the Pharmaceutical Wholesale division fell 7.9% to $5.3 billion. Revenues from the Retail Pharmacy International division also dropped 10.3% to $2.8 billion. Moreover, Walgreens Boots filled 255.2 million prescriptions (including immunizations) on a 30-day adjusted basis in the quarter, reflecting an increase of 8.5% over third quarter of fiscal 2016.
Major Factors: Per management, Walgreens Boots third quarter 2017 results were in line with its expectations. This is on account of the company’s strategic tie-ups which brought more patients to its U.S. pharmacies. This also led to its highest reported quarterly retail prescription market share in the U.S. Management is currently optimistic about its ongoing cost transformation program and remains confident about the long term growth of the company. The company has increased the lower end of its outlook for fiscal year 2017 by 8 cents per share and anticipates adjusted earnings per share of $4.98 to $5.08.
Stock Price: Following the earnings release, share prices rose 3.77% during the pre-market trading session.
Check back later for our full write up on this Walgreens Boots earnings report later!
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>